Psyence Biomedical Ltd is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
PBM stock price ended at $3.09 on 星期五, after rising 9.96%
On the latest trading day Feb 13, 2026, the stock price of PBM rose by 9.96%, climbing from $2.79 to $3.09. During the session, the stock saw a volatility of 11.11%, with prices oscillating between a daily low of $2.79 and a high of $3.10. Notably, trading volume dropped by 52.8K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 135.4K shares were traded, equating to a market value of approximately $3.1M.